Drug Interactions of Selected Drugs Used by Patients with Diabetes Mellitus

Česká verzia

Authors: M. Prokeš; J. Suchopár
Authors place of work: INFOPHARM a. s., Praha, ředitel PharmDr. Josef Suchopár
Published in the journal: Vnitř Lék 2009; 55(4): 395-402
Category:

Summary

Many patients with diabetes mellitus are treated by various medicinal products, which can in some cases lead to drug interaction. In this paper drug interactions of antidiabetics are summarised and most important drug interactions of other drugs frequently prescribed to diabetics are mentioned: drugs acting on the renin‑angiotensin system and statins.

Key words:
drug interactions – antidiabetics – patients with diabetes mellitus

Zdroje

1. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15–19.

2. Sawicki PT, Siebenhofer A. Betablocker treatment in diabetes mellitus. J Intern Med 2001; 250: 11–17.

3. Kotler MN, Berman L, Rubenstein AH. Hypoglycaemia precipitated by propranolol. Lancet 1966; 2: 1389–1390.

4. Deacon SP, Karunanayake A, Bernett D. Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics. Br Med J 1977; 2: 1255–1257.

5. McMurtry RJ. Letter: Propranolol, hypoglycemia, and hypertensive crisis. Ann Intern Med 1974; 80: 669–670.

6. Samii K, Ciancioni C, Rottembourg J et al. Letter: Severe hypoglycaemia due to beta‑blocking drugs in haemodialysis patients. Lancet 1976; 1: 545–546.

7. Angelo-Nielsen K. Timolol topically and diabetes mellitus. JAMA 1980; 244: 2263.

8. Newman RJ. Comparison of propranolol, metoprolol, and acebutolol in insulin‑induced hypoglycaemia. Br Med J 1976; 2: 447–449.

9. Veenstra J, van der Hulst JP, Wildenborg IH et al. Effect of antihypertensive drugs on insulin absorption. Diabetes Care 1991; 14: 1089–1092.

10. Shorr RI, Ray WA, Daugherty JR et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997; 278: 40–43.

11. Herings RM, de Boer A, Stricker BH et al. Hypoglycaemia associated with the use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345: 1195–1198.

12. Ryan JR, LaCorte W, Jain A et al. Hypertension in hypoglycemic diabetics treated with beta‑adrenergic antagonists. Hypertension 1985; 7: 443–446.

13. Shepherd AM, Lin MS, Keeton TK. Hypoglycemia‑induced hypertension in a diabetic patient on metoprolol. Ann Intern Med 1981; 94: 357–358.

14. Ostman J, Arner P, Haglund K et al. Effect of metoprolol and alprenolol on the metabolic, hormonal, and haemodynamic response to insulin‑induced hypoglycaemia in hypertensive, insulin‑dependent diabetics. Acta Med Scand 1982; 211: 381–385.

15. Efficacy of atenolol and capropril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabets Study Group. BMJ 1998; 317: 713–720.

16. McMurtry RJ. Letter: Propranolol, hypoglycemia, and hypertensive criris. Ann Intern Med 1974; 80: 669–670.

17. Kaye R, Athreya BH, Kunzmann EE et al. Antipyretics in patients with juvenile diabetes mellitus. Comparison of salicylate and a salicylate substitute (experimental preparation PAJ-102). Am J Dis Child 1966; 112: 52–55.

18. Reid J, Lightbody TD. The insulin equivalence of salicylate. Br Med J 1959; 1: 897–900.

19. Kubacka RT, Antal EJ, Juhl RP et al. Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects. Ann Pharmacother 1996; 30: 20–26.

20. Cattaneo AG, Caviezel F, Pozza G. Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man. Int J Clin Pharmacol Ther Toxicol 1990; 28: 229–234.

21. David DS, Cheigh JS, Braun DW Jr et al. HLA‑A28 and steroid‑induced diabetes in renal transplant patients. JAMA 1980; 243: 532–533.

22. Faul JL, Tormey W, Burke C et al. High dose inhaled corticosteroids and dose dependent loss of diabetic control. BMJ 1998; 317: 1491.

23. Faul JL, Cormican LJ, Tormey VJ et al. Deteriorating diabetic control associated with high‑dose inhaled budesonide. Eur Respir J 1999; 14: 242–243.

24. Gomez EC, Frost P. Induction of glycosuria and hyperglycemia by topical corticosteroid therapy. Arch Dermatol 1976; 112: 1559–1562.

25. Roberge RJ, Kaplan R, Frank R et al. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. ANN Emerg Med 2000; 36: 160–163.

26. Menzies DJ, Dorsainvil PA, Cunha BA et al. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002; 113: 232–234.

27. Prozac (fluoxetin). Eli Lilly and Company Ltd. UK Summary of product characteristics, March 2007.

28. Sawka AM, Burgart V, Zimmerman D. Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride. J Pediatr 2000; 136: 394–396.

29. Takhar J, Williamson P. Hypoglycemia associated with high doses of sertraline and sulphonylurea compound in a noninsulin‑dependent diabetes mellitus patient. Can J Clin Pharmacol 1999; 6: 12–14.

30. Lao B, Czyzyk A, Szutowski M et al. Alcohol tolerance in patients with non‑insulin‑dependent (type 2) diabetes treated with sulphonylurea derivates. Arzheim Forsch 1994; 44: 727–734.

31. Souhrn údajů o přípravku: Dirastan (tolbutamid), Zentiva, 2004 (AISLP 2006/1).

32. McCartney MM, Gilbert FJ, Murchison LE et al. Metformin and contrast media – a dangerous combination? Clin Radiol 1999; 54: 29–33.

33. Souhrn údajů o přípravku: Metformin Léčiva (metformin). Zentiva 2004 (AISLP 2005/2).

34. Niemi M, Kajosaari LI, Neuvonen M et al. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2003; 57: 441–447.

35. Niemi M, Neuvonen PJ, Kivistö KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2001; 70: 58–65.

36. Niemi M, Backman JT, Neuvonen M et al. Effects of gemfibrozil, intraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003; 46: 347–351.

37. Souhrn údajů o přípravku: Novonorm (repaglinid). Novo Nordisk 2004 (AISLP, 2005/2).

38. Miura T, Ueno K, Tanaka K et al. Impairment of absorption of digoxin by acarbose. J Clin Pharmacol 1998; 38: 654–657.

39. Hruska MW, Cheong JA, Langaee Ty et al. Effect if St. John’s wort (Hypericium perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2005: 77: PI–104 (abstract).

40. Krishnaiah YS, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol 1994; 37: 205–207.

41. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990; 12 (Suppl 3): S327–S333.

42. Niemi M, Backman JT, Neuvonen M et al. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001; 69: 194–200.

43. Guazzi MD, Campodonico J, Celeste F et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther 1998; 63: 79–86.

44. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti‑inflammatory drugs affect blood presure? A meta‑analysis. Ann Intern Med 1994; 121: 289–300.

45. Bouvy ML, Heerding ER, Hoes AW et al. Effects onf NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. Drug Saf 2003; 26: 983–989.

46. Kurata C, Uehara A, Sugi T et al. Syncope caused by nonsteroidal anti‑inflamatory drugs and angiotensin‑converting enzyme inhibitors. Jpn Circ J 1999; 63: 1002–1003.

47. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717.

48. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 543–551.

49. Wrenger E, Müller R, Moesenthin M et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327: 147–149.

50. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140–1146.

51. Souhrn údajů o přípravku: Nizoral (ketokonazol). Janssen Cilag 2006 (AISLP, 2006/4). Souhrn údajů o přípravku Zocor (simvastatin). MSD 2008 (AISLP, 2008/2).

52. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interation with CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332–341.

53. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54–61.

54. Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49–53.